Pressure BioSciences creates two new convertible preferred series with forced conversion and voting features

PRESSURE BIOSCIENCES INC

Series BB: 1,000 shares, 10,000 votes per share, convertible to 10,000 common shares each.
Series CC: 2,000 shares, 8% annual dividend on $25,000 liquidation preference per share.
Series CC converts at $2.50/share; forced conversion if VWAP >= 300% of $2.50 for 10/15 trading days or exchange listing.
Both series have a 4.99% conversion restriction on beneficial ownership (waivable with 61 days' notice).
Series BB ranks junior to AA/CC; Series CC ranks pari passu with AA and senior to common stock.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PRESSURE BIOSCIENCES INC: Filed Articles of Amendment to Restated Articles of Organization to designate Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock (effective 2023-05-01).

Change: charter amendment
Effective: 2023-05-01

Exact text from the filing

On May 1, 2023, Pressure BioSciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization (the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate 1,000 shares of its Preferred Stock as Series BB Convertible Preferred Stock, par value $0.01 per share (the “Series BB Preferred Stock”) and 2,000 shares of Preferred Stock as Series CC Convertible Preferred Stock, par value $0.01 per share (the “Series CC Preferred Stock”).

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001493152-23-015632

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.